Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 12, 2004. The report details changes in directors' interests in the company's Ordinary Shares and American Depositary Receipts (ADRs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance disclosures regarding share ownership changes rather than financial performance.
Material Changes
- Employee Trust Transfer: On January 8, 2004, the GlaxoSmithKline Employee Trust transferred 16,422 Ordinary shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
- Director ADR Reinvestment: On January 6, 2004, dividends paid to Ordinary Share ADR holders were reinvested through the US Global BuyDirect Plan. This resulted in new beneficial interests for Directors Mr. D F McHenry (0.2594 ADRs) and Mr. J H McArthur (31.8955 ADRs) at a price of $45.8689 per ADR.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document serves as a statutory notification of share transactions.
Investor Verification Checklist
- Verify the total number of shares held by the GlaxoSmithKline Employee Trust following the January 8 transfer.
- Confirm the aggregate impact of the dividend reinvestment plan on the total share count for the reporting period.
- Review the full 20-F annual report for comprehensive financial data not included in this 6-K filing.